George Buchman

Vice President, Pre-Clinical and Process Development • Catalent Cell and Gene Therapy

Buchman joined Catalent through its acquisition of Paragon Gene Therapy in 2019. He has more than 30 years of experience in the biotech industry and has held roles at companies including Life Technologies (now Thermo Fisher), Celera Genomics and GeneLogic. Dr. Buchman obtained a bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and a doctorate in biochemistry from University of Maryland.  

Also Speaking

Eytan Abraham

Vice President & Business Head, Cell Therapy, Gene Therapy • Nucleic Acids

Jian Irish

President and Chief Operating Officer • Metagenomi

Rebecca Lim

Senior Vice President – Scientific Affairs • Prescient Therapeutics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.